Skip to main content
. 2021 Feb 25;13(3):302. doi: 10.3390/pharmaceutics13030302

Figure 2.

Figure 2

Relationship between pharmaceutical formulations and pharmacokinetic/pharmacodynamic properties affecting efficacy and safety of repurposed agents in respiratory viral diseases, including COVID-19 setting. PK, pharmacokinetic; PD, pharmacodynamic.